These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 34571362)

  • 1. NfL predicts relapse-free progression in a longitudinal multiple sclerosis cohort study.
    Uphaus T; Steffen F; Muthuraman M; Ripfel N; Fleischer V; Groppa S; Ruck T; Meuth SG; Pul R; Kleinschnitz C; Ellwardt E; Loos J; Engel S; Zipp F; Bittner S
    EBioMedicine; 2021 Oct; 72():103590. PubMed ID: 34571362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study.
    Bittner S; Steffen F; Uphaus T; Muthuraman M; Fleischer V; Salmen A; Luessi F; Berthele A; Klotz L; Meuth SG; Bayas A; Paul F; Hartung HP; Linker R; Heesen C; Stangel M; Wildemann B; Then Bergh F; Tackenberg B; Kuempfel T; Weber F; Zettl UK; Ziemann U; Tumani H; Groppa S; Mühlau M; Lukas C; Hemmer B; Wiendl H; Gold R; Zipp F;
    EBioMedicine; 2020 Jun; 56():102807. PubMed ID: 32460167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Age-corrected neurofilament light chain ratio decreases but does not predict relapse in highly active multiple sclerosis patients initiating natalizumab treatment.
    Højsgaard Chow H; Petersen ER; Olsson A; Hejgaard Laursen J; Bredahl Hansen M; Oturai AB; Soelberg Sørensen P; Bach Søndergaard H; Sellebjerg F
    Mult Scler Relat Disord; 2024 Aug; 88():105701. PubMed ID: 38889559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of elevated sNFL in a real-world setting: Results on 908 patients with different multiple sclerosis types and treatment conditions.
    Bava CI; Valentino P; Malucchi S; Bottero R; Martire S; Sapio AD; Bertolotto A
    Mult Scler Relat Disord; 2024 Aug; 88():105748. PubMed ID: 38959590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum NfL and GFAP are weak predictors of long-term multiple sclerosis prognosis: A 6-year follow-up.
    Ayrignac X; Aouinti S; Vincent T; Carra-Dallière C; Charif M; Duflos C; Hirtz C; Dos Santos A; Menjot de Champfleur N; Labauge P; Lehmann S
    Mult Scler Relat Disord; 2024 Sep; 89():105747. PubMed ID: 39053395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Faces of "Too Late"-A Surprisingly Progressive Cohort of "Stable" Relapsing Remitting Multiple Sclerosis Patients.
    Ciubotaru A; Grosu C; Alexa D; Covali R; Maștaleru A; Leon MM; Schreiner TG; Ghiciuc CM; Roman EM; Azoicăi D; Ignat EB
    Medicina (Kaunas); 2024 Aug; 60(9):. PubMed ID: 39336442
    [No Abstract]   [Full Text] [Related]  

  • 7. Early neurofilament light and glial fibrillary acidic protein levels improve predictive models of multiple sclerosis outcomes.
    Bose G; Healy BC; Saxena S; Saleh F; Paul A; Barro C; Lokhande HA; Polgar-Turcsanyi M; Anderson M; Glanz BI; Guttmann CRG; Bakshi R; Weiner HL; Chitnis T
    Mult Scler Relat Disord; 2023 Jun; 74():104695. PubMed ID: 37060852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study.
    Benkert P; Meier S; Schaedelin S; Manouchehrinia A; Yaldizli Ö; Maceski A; Oechtering J; Achtnichts L; Conen D; Derfuss T; Lalive PH; Mueller C; Müller S; Naegelin Y; Oksenberg JR; Pot C; Salmen A; Willemse E; Kockum I; Blennow K; Zetterberg H; Gobbi C; Kappos L; Wiendl H; Berger K; Sormani MP; Granziera C; Piehl F; Leppert D; Kuhle J;
    Lancet Neurol; 2022 Mar; 21(3):246-257. PubMed ID: 35182510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Central nervous system atrophy predicts future dynamics of disability progression in a real-world multiple sclerosis cohort.
    Tsagkas C; Naegelin Y; Amann M; Papadopoulou A; Barro C; Chakravarty MM; Gaetano L; Wuerfel J; Kappos L; Kuhle J; Granziera C; Sprenger T; Magon S; Parmar K
    Eur J Neurol; 2021 Dec; 28(12):4153-4166. PubMed ID: 34487400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum Neurofilament Light and GFAP Are Associated With Disease Severity in Inflammatory Disorders With Aquaporin-4 or Myelin Oligodendrocyte Glycoprotein Antibodies.
    Chang X; Huang W; Wang L; ZhangBao J; Zhou L; Lu C; Wang M; Yu J; Li H; Li Y; Zhao C; Lu J; Quan C
    Front Immunol; 2021; 12():647618. PubMed ID: 33796113
    [No Abstract]   [Full Text] [Related]  

  • 11. Profiling individual clinical responses by high-frequency serum neurofilament assessment in MS.
    Akgün K; Kretschmann N; Haase R; Proschmann U; Kitzler HH; Reichmann H; Ziemssen T
    Neurol Neuroimmunol Neuroinflamm; 2019 May; 6(3):e555. PubMed ID: 31119188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A low vitamin D status at diagnosis is associated with an early conversion to secondary progressive multiple sclerosis.
    Muris AH; Rolf L; Broen K; Hupperts R; Damoiseaux J; Smolders J
    J Steroid Biochem Mol Biol; 2016 Nov; 164():254-257. PubMed ID: 26598277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum GFAP and NfL Levels Differentiate Subsequent Progression and Disease Activity in Patients With Progressive Multiple Sclerosis.
    Barro C; Healy BC; Liu Y; Saxena S; Paul A; Polgar-Turcsanyi M; Guttmann CRG; Bakshi R; Kropshofer H; Weiner HL; Chitnis T
    Neurol Neuroimmunol Neuroinflamm; 2023 Jan; 10(1):. PubMed ID: 36376097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term prognostic value of longitudinal measurements of blood neurofilament levels.
    Häring DA; Kropshofer H; Kappos L; Cohen JA; Shah A; Meinert R; Leppert D; Tomic D; Kuhle J
    Neurol Neuroimmunol Neuroinflamm; 2020 Sep; 7(5):. PubMed ID: 32817406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort.
    Tilling K; Lawton M; Robertson N; Tremlett H; Zhu F; Harding K; Oger J; Ben-Shlomo Y
    Health Technol Assess; 2016 Oct; 20(81):1-48. PubMed ID: 27817792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurofilament Light Chain Serum Levels Mirror Age and Disability in Secondary Progressive Multiple Sclerosis: A Cross-Sectional Study.
    Husseini L; Jung J; Boess N; Kruse N; Nessler S; Stadelmann C; Metz I; Haupts M; Weber MS
    Neurol Neuroimmunol Neuroinflamm; 2024 Sep; 11(5):e200279. PubMed ID: 38991171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis.
    Meier S; Willemse EAJ; Schaedelin S; Oechtering J; Lorscheider J; Melie-Garcia L; Cagol A; Barakovic M; Galbusera R; Subramaniam S; Barro C; Abdelhak A; Thebault S; Achtnichts L; Lalive P; Müller S; Pot C; Salmen A; Disanto G; Zecca C; D'Souza M; Orleth A; Khalil M; Buchmann A; Du Pasquier R; Yaldizli Ö; Derfuss T; Berger K; Hermesdorf M; Wiendl H; Piehl F; Battaglini M; Fischer U; Kappos L; Gobbi C; Granziera C; Bridel C; Leppert D; Maleska Maceski A; Benkert P; Kuhle J
    JAMA Neurol; 2023 Mar; 80(3):287-297. PubMed ID: 36745446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum Neurofilament Identifies Patients With Multiple Sclerosis With Severe Focal Axonal Damage in a 6-Year Longitudinal Cohort.
    Steffen F; Uphaus T; Ripfel N; Fleischer V; Schraad M; Gonzalez-Escamilla G; Engel S; Groppa S; Zipp F; Bittner S
    Neurol Neuroimmunol Neuroinflamm; 2023 Jan; 10(1):. PubMed ID: 36411080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Involvement of cytotoxic Eomes-expressing CD4
    Raveney BJE; Sato W; Takewaki D; Zhang C; Kanazawa T; Lin Y; Okamoto T; Araki M; Kimura Y; Sato N; Sano T; Saito Y; Oki S; Yamamura T
    Proc Natl Acad Sci U S A; 2021 Mar; 118(11):. PubMed ID: 33836594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis.
    Siller N; Kuhle J; Muthuraman M; Barro C; Uphaus T; Groppa S; Kappos L; Zipp F; Bittner S
    Mult Scler; 2019 Apr; 25(5):678-686. PubMed ID: 29542376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.